PSivida Reports Interim Data From Uveitis Study - Quick Facts

(RTTNews) - pSivida Corp. (PSDV) reported interim data from an investigator-sponsored Phase I/II study of pSivida's injectable micro-insert in patients with posterior uveitis, an inflammatory disease of one of the layers of the eye. The company said through the first 12 months of enrollment in this study, none of the treated eyes had a recurrence of uveitis, and inflammation had been reduced in all treated eyes.

The interim data showed that the micro-inserts were well-tolerated and the observed safety profile was consistent with the short-term safety profile reported in clinical studies of ILUVIEN in DME subjects.

With one exception, intraocular pressure measurements of treated eyes had all remained in the normal range. One treated eye required surgery to control pressure.